Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun 20;121(25):5098-103.
doi: 10.1182/blood-2012-10-464198. Epub 2013 Apr 1.

Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease

Yoshihiro Inamoto  1 , Barry E Storer, Effie W Petersdorf, J Lee Nelson, Stephanie J Lee, Paul A Carpenter, Brenda M Sandmaier, John A Hansen, Paul J Martin, Mary E D Flowers
Affiliations

Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease

Yoshihiro Inamoto et al. Blood. .

Abstract

Sclerotic chronic graft-versus-host disease (GVHD) can result in disability after allogeneic hematopoietic cell transplantation. We assessed the incidence and risk factors of sclerosis and its association with transplant outcomes among 977 consecutive patients treated with systemic immunosuppression for chronic GVHD. Sclerosis was defined when cutaneous sclerosis, fasciitis, or joint contracture was first documented in the medical record. Seventy (7%) patients presented with sclerosis at the time of initial systemic treatment for chronic GVHD, and the cumulative incidence of sclerosis increased to 20% at 3 years. Factors associated with an increased risk of sclerosis included the use of a mobilized blood cell graft and a conditioning regimen with > 450 cGy total body irradiation. Factors associated with a decreased risk of sclerosis included the use of an HLA-mismatched donor and a major ABO-mismatched donor. Development of sclerosis was associated with longer time to withdrawal of immunosuppressive treatment but not with risks of overall mortality, nonrelapse mortality, or recurrent malignancy. We found a substantial incidence of sclerosis in patients with chronic GVHD. Development of sclerosis can cause disability but does not affect mortality or recurrent malignancy in patients with chronic GVHD.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cumulative incidence of sclerosis after initial systemic treatment for chronic GVHD. Seventy (7%) of the 977 patients presented with sclerotic features at the time of initial systemic treatment for chronic GVHD.
See this image and copyright information in PMC

References

    1. Gratwohl AA, Moutsopoulos HM, Chused TM, Akizuki M, Wolf RO, Sweet JB, Deisseroth AB. Sjögren-type syndrome after allogeneic bone-marrow transplantation. Ann Intern Med. 1977;87(6):703–706. - PubMed
    1. Shulman HM, Kleiner D, Lee SJ, et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant. 2006;12(1):31–47. - PubMed
    1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360(19):1989–2003. - PubMed
    1. Fleming JN, Shulman HM, Nash RA, Johnson PY, Wight TN, Gown A, Schwartz SM. Cutaneous chronic graft-versus-host disease does not have the abnormal endothelial phenotype or vascular rarefaction characteristic of systemic sclerosis. PLoS ONE. 2009;4(7):e6203. - PMC - PubMed
    1. Biedermann BC, Sahner S, Gregor M, Tsakiris DA, Jeanneret C, Pober JS, Gratwohl A. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet. 2002;359(9323):2078–2083. - PubMed

Publication types

MeSH terms